Search

Your search keyword '"Calafat, M"' showing total 216 results

Search Constraints

Start Over You searched for: Author "Calafat, M" Remove constraint Author: "Calafat, M"
216 results on '"Calafat, M"'

Search Results

1. A Bulk-Controlled Low-Voltage CMOS Quadrature Oscillator

2. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry

3. P168 Specialized pro-resolving lipid mediator Resolvin D1 and omega 6 dihomo-γ-linolenic acid are unable to solve inflammation in the creeping fat of patients with severe postoperative recurrence in Crohn's disease

4. P081 The integration of transcriptomic and microbiomic data links several intestinal bacterial families with key biological functions in the development of postoperative recurrence in Crohn's disease

5. P419 Proximal Crohn’s disease location is associated with a more benign course of perianal Crohn’s disease (the PERIAPROX study)

6. P1115 Characteristics and management of pyoderma gangrenosum and erythema nodosum in patients with inflammatory bowel disease: PIONOSO multicenter study

7. P987 Impact of Crohn’s Disease Location on Biologic Therapy Persistence and the Risk of Intestinal Surgery: Insights from the ENEIDA Registry (the DISCOLOC Study)

8. P211 Impact of celiac disease on the outcome of Inflammatory Bowel Disease

10. P778 Effectiveness and safety of a second-line rescue therapy for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)

12. P675 Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, safety and impact of extraintestinal manifestations and immunomediated diseases

13. P386 Clinical presentation, management, and evolution of lymphomas in patients with Inflammatory Bowel Disease: an ENEIDA registry study

16. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case‐control study

17. OP034 The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registry

19. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry

20. Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease

21. Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?

22. Correction to: Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera

23. Clinical outcomes in familial versus sporadic inflammatory bowel disease diagnosed in the era of biological therapies. Prospective data from the ENEIDA registry

24. Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD)

25. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

26. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

27. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry

28. DOP78 Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD)

29. P519 Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease

30. P290 Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?

31. P410 Safety of biological drugs for inflammatory bowel disease in elderly patients

32. P654 Clinical outcomes in familial versus sporadic inflammatory bowel disease diagnosed in the era of biological therapies. Prospective data from the ENEIDA registry

33. P373 Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, impact of extraintestinal manifestations and immunomediated diseases and safety

34. P481 Profile of elderly patients in which biological drugs are used for the treatment of inflammatory bowel disease

36. Effectiveness and safety of ustekinumab in elderly patients: Real world evidence from ENEIDA registry

37. effectiveness and safety of biological therapies in elderly inflammatory bowel diseases patients results from a multi center study of Geteccu

38. Management and outcome of postoperative Crohn's Disease in the elderly as compared to young adults: Data from Eneida registry

39. Long-term outcomes of enterocutaneous fistula complicating Crohn's Disease: The ECUFIT study from GETECCU

40. Inflammatory complications of the pouch, and therapetic requirements after colectomy in patients with ulcerative colitis. Results from the RESERVO Study of GETECCU

42. Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry

43. Una tarea para la escuela de negocios del siglo XXI: estudiantes computacionalmente competentes

44. P104 Inflammatory complications of the pouch, and therapetic requirements after colectomy in patients with ulcerative colitis. Results from the RESERVO Study of GETECCU

45. P262 Effectiveness and safety of ustekinumab in elderly patients: Real world evidence from ENEIDA registry

46. P338 effectiveness and safety of biological therapies in elderly inflammatory bowel diseases patients results from a multi center study of Geteccu

47. DOP31 Management and outcome of postoperative Crohn’s Disease in the elderly as compared to young adults: Data from Eneida registry

48. P458 Effectiveness of biological therapy for pouchitis and other inflammatory complications ot the pouch. And the question of a second Anti-TNF after failure? Results from the RESERVO Study of GETECCU

49. P372 Effectiveness and safety of immunosuppressants for pouch disorders: results from the RESERVO Study of GETECCU

50. DOP32 Long-term outcomes of enterocutaneous fistula complicating Crohn’s Disease: The ECUFIT study from GETECCU

Catalog

Books, media, physical & digital resources